On February 1, 2022, Zhang, Chen; Liao, Yuting; He, Ping; Chen, Xiaogang; Xuan, Zhaoli; Ye, Fei; Tang, Pingming; Wan, Songlin; Li, Yao; Ni, Jia; Yan, Pangke published a patent.COA of Formula: C15H29N3O2 The title of the patent was Preparation of BTK inhibitor cyclic derivative and its pharmaceutical application in treatment of BTK-related diseases. And the patent contained the following:
The present invention relates to preparation of BTK inhibitor cyclic derivative and its pharmaceutical application in treatment of BTK-related diseases. In particular, the BTK inhibitor ring derivative B-L-K (wherein, L = -Ak1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak5-; Ak1 – Ak5 = CH2, O, -NRb0-, C=O, C=C or bond; Cy1 – Cy4 = optionally substituted 3-12 membered heterocycle, optionally substituted 3-12 membered cycloalkyl, optionally substituted 6-10 membered aryl, or bond; B = B1-W1-B2-B3-B4- or I, when B = B1-W1-B2-B3-B4-, Cy1, Cy2, Cy3, and Cy4 cannot be bonds at the same time; when B = B1-W1-B2-B3-B4-, and Ak1, Ak2, Ak3, Ak4 or Ak5 are not bonds, they cannot be directly connected to each other). Further, (B1 and B2 = optionally substituted 6-membered heteroaromatic ring or phenyl; W1 = -O-, -S-, -NH-, -NHCO- or -CONH-; B3 = optionally substituted heterocyclic ring; B4 = optionally substituted 4-7-membered monocycloalkyl, optionally substituted 6-12-membered spirocycloalkyl, optionally substituted 5-10-membered cycloalkyl derivative etc.; B5 or B6 = optionally substituted Ph or 5-6-membered heteroaryl; Rb6 = H, C1-4 alkyl, halogen-substituted C1-4 alkyl or hydroxy-substituted C1-4 alkyl; Rb7 and Rb8 = H, F, Cl, Br, I, OH, NH2, CN, CF3, -C(=O)NH2 etc.; m = 0, 1 or 2; K = heterocyclic group, cycloalkyl carbonyl-group, aralkyl carbonyl-group etc.) or stereoisomer, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof were prepared The inventive BTK inhibitor cyclic derivatives are useful for treating BTK-related diseases such as tumors or autoimmune system diseases. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).COA of Formula: C15H29N3O2
The Article related to azaheterocyclic compound preparation btk inhibitor antitumor autoimmune disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C15H29N3O2
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics